Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life

References

• RindiGThe ENRTS guidelines: the new TNM classification systemTumori201096580680921302636
   PubMedGoogle Scholar
• LüttgesJWhat’s new? The 2010 WHO classification for tumours of the pancreasPathologe201132Suppl 233233621915659
   PubMedGoogle Scholar
• ReubiJCSchärJCWaserBAffinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic useEur J Nucl Med200027327328210774879
   PubMedGoogle Scholar
• VirgoliniIAmbrosiniVBomanjiJBProcedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATEEur J Nucl Med Mol Imaging201037102004201020596866
   PubMedGoogle Scholar
• van EssenMSundinAKrenningEPKwekkeboomDJNeuroendocrine tumours: the role of imaging for diagnosis and therapyNat Rev Endocrinol201410210211424322649
   PubMedGoogle Scholar
• ValkemaRDe JongMBakkerWHPhase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experienceSemin Nucl Med200232211012211965606
   PubMed Web of Science ®Google Scholar
• ImhofABrunnerPMarincekNResponse, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersJ Clin Oncol201129172416242321555692
   PubMed Web of Science ®Google Scholar
• BushnellDLJrO’DorisioTMO’DorisioMS90Y-edotreotide for metastatic carcinoid refractory to octreotideJ Clin Oncol201028101652165920194865
   PubMed Web of Science ®Google Scholar
• BodeiLCremonesiMGranaCMYttrium-labelled peptides for therapy of NETEur J Nucl Med Mol Imaging201239Suppl 1S93S10222388625
   PubMedGoogle Scholar
• BodeiLCremonesiMGranaCMPeptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I–II studyEur J Nucl Med Mol Imaging201138122125213521892623
   PubMed Web of Science ®Google Scholar
• HörschDEzziddinSHaugAPeptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registryRecent Results Cancer Res201319445746522918775
   PubMedGoogle Scholar
• CremonesiMFerrariMDi DiaARecent issues on dosimetry and radiobiology for peptide receptor radionuclide therapyQ J Nucl Med Mol Imaging201155215516721386788
   PubMedGoogle Scholar
• Jiménez-FonsecaPCarmona-BayonasAMartín-PérezEHealth-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumorsCancer Metastasis Rev201534338140026245646
   PubMed Web of Science ®Google Scholar
• BodeiLMueller-BrandJBaumRPThe joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEur J Nucl Med Mol Imaging201340580081623389427
   PubMed Web of Science ®Google Scholar
• de JongMKrenningENew advances in peptide receptor radionuclide therapyJ Nucl Med200243561762011994523
   PubMed Web of Science ®Google Scholar
• BernardBFKrenningEPBreemanWAD-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptakeJ Nucl Med19973812192919339430472
   PubMedGoogle Scholar
• DaleRUse of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapyCancer Biother Radiopharm200419336337015285884
   PubMedGoogle Scholar
• BaroneRBorson-ChazotFValkemaRPatient specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationshipJ Nucl Med200546Suppl 199S106S15653658
   PubMedGoogle Scholar
• BodeiLCremonesiMFerrariMLong-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEur J Nucl Med Mol Imaging200835101847185618427807
   PubMed Web of Science ®Google Scholar
• ValkemaRPauwelsSKvolsLKSurvival and responsafter peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrinetumorsSemin Nucl Med200636214715616517236
   PubMed Web of Science ®Google Scholar
• KwekkeboomDJde HerderWWKamBLTreatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survivalJ Clin Oncol200826132124213018445841
   PubMed Web of Science ®Google Scholar
• EzziddinSAttassiMYong-HingCJPredictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotateJ Nucl Med201455218319024434296
   PubMed Web of Science ®Google Scholar
• SeveriSNanniOBodeiLRole of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumoursEur J Nucl Med Mol Imaging201340688188823443937
   PubMedGoogle Scholar
• PaganelliGSansoviniMAmbrosettiA177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II studyEur J Nucl Med Mol Imaging2014411845185124615468
   PubMed Web of Science ®Google Scholar
• BaumRPKlugeAWKulkarniH[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: a phase-II studyTheranostics20166450151026941843
   PubMed Web of Science ®Google Scholar
• ForrerFUusijärviHStorchDMaeckeHRMueller-BrandJTreatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOCJ Nucl Med2005461310131616085587
   PubMed Web of Science ®Google Scholar
• PachDSowa-StaszczakAKunikowskaJRepeated cycles of peptide receptor radionuclide therapy (PRRT)-results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NETRadiother Oncol20121021455021885142
   PubMedGoogle Scholar
• van EssenMKrenningEPKamBLde HerderWFeeldersRAKwekkeboomDJSalvage therapy with 177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumorsJ Nucl Med201051338339020150247
   PubMed Web of Science ®Google Scholar
• SabetAHaslerudTPapeUFOutcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumoursEur J Nucl Med Mol Imaging201441220521024030668
   PubMed Web of Science ®Google Scholar
• PrasadVBrennerWModlinIMHow smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician’s perspectiveEur J Nucl Med Mol Imaging201441220220424196915
   PubMedGoogle Scholar
• SeveriSSansoviniMIannielloAFeasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOCEur J Nucl Med Mol Imaging201542131955196326112388
   PubMed Web of Science ®Google Scholar
• SarnelliAGuerrieroFBottaFTherapeutic schemes in177Lu and 90Y-PRRT: radiobiological considerationsQ J Nucl Med Mol Imaging Epub11172015
   PubMedGoogle Scholar
• KesavanMClaringboldPGHarvey TurnerJHematological toxicity of combined 177Lu radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long term follow upNeuroendocrinology201499210811724714208
   PubMedGoogle Scholar
• BodeiLKiddMModlinIMMeasurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumorsEur J Nucl Med Mol Imaging201643583985126596723
   PubMed Web of Science ®Google Scholar
• GarkavijMNickelMSjorgreen-GleisnerK177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendrocrine tumors: Analysis of dosimetry with impact on future therapeutic strategyCancer20101164 Suppl1084109220127957
   PubMed Web of Science ®Google Scholar
• SwärdCBernhardtPAhlmanH[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidneyWorld J Surg20103461368137220066413
   PubMed Web of Science ®Google Scholar
• BodeiLCremonesiMGranaCMPeptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I–II studyEur J Nucl Med Mol Imaging201138122125213521892623
   PubMed Web of Science ®Google Scholar